Pod Save America Hosts Call on Democrats to Cut All Israel Military Aid, No Longer Accept AIPAC Funding
Jews, Israelis Targeted in Austria Amid Surge in Antisemitic Incidents; Local Jewish Community Calls for Action
‘All of Our Strength’: Over 1,000 Pro-Israel Activists Gather in DC for Solidarity Conference
‘Devastated’: Wesley LePatner, Killed in Manhattan Mass Shooting, Was a Jewish Communal, Philanthropic Leader
Sen. Angus King Vows to No Longer Vote for Israel Military Aid Until Gaza Conditions Improve
Europe Won’t Pressure Israel to ‘Commit Suicide’ Amid Gaza Backlash, Palestinian State Push, Says Israeli FM
Israel’s National Soccer Coach Attacked in Athens Before Soccer Fans Chant ‘F–K Israel, Free Palestine’ at Match
New York Judge Sentences Neo-Nazi to 5 Years for Livestreaming Bomb Threats Against Jewish Hospitals
US Pressures Lebanon to Issue Cabinet Decision to Disarm Hezbollah Before Talks Continue
UK Plans to Recognize Palestinian State in September Unless Israel Meets Conditions, Starmer Says
Teva, Amgen End Dispute Over Generic Cinacalcet HCl Tablets
Error: Contact form not found.
by Reuters and Algemeiner Staff
A Teva building in Jerusalem, Dec. 14, 2017. Photo: Reuters / Ammar Awad.
Teva Pharmaceutical Industries Ltd said on Thursday it will pay an undisclosed amount to settle an ongoing dispute with Amgen Inc over its generic Cinacalcet HCl product.
The Israel-based drugmaker has also agreed to stop selling the generic product until its license date in mid-year 2021, or earlier under certain circumstances.
Teva said it recently received approval for the generic product and launched it in the United States.
Cinacalcet hydrochloride is approved for the treatment of secondary hyperparathyroidism in adults with chronic kidney disease on dialysis and for the treatment of higher levels of calcium in adults with parathyroid carcinoma.
